<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="rTMS_discussion_static_groups.enl" path="/Volumes/Main/Working/Kielar_MetaAnalysis_2020/rTMS_discussion_static_groups.enl">rTMS_discussion_static_groups.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>73</rec-number><foreign-keys><key app="EN" db-id="sdaareav6zpdpeep0rb5trdqdxpwpxt225tv">73</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Contents Vol. 67, 2015</style></title><secondary-title><style face="normal" font="default" size="100%">Folia Phoniatrica et Logopaedica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Folia Phoniatrica et Logopaedica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">I-IV</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Medical Sciences--Otorhinolaryngology</style></keyword><keyword><style face="normal" font="default" size="100%">Rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">Feasibility studies</style></keyword><keyword><style face="normal" font="default" size="100%">Speaking</style></keyword><keyword><style face="normal" font="default" size="100%">Drug dosages</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">Information storage</style></keyword><keyword><style face="normal" font="default" size="100%">Aging</style></keyword><keyword><style face="normal" font="default" size="100%">Editors</style></keyword><keyword><style face="normal" font="default" size="100%">Copyright</style></keyword><keyword><style face="normal" font="default" size="100%">Speech disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Dysphagia</style></keyword><keyword><style face="normal" font="default" size="100%">Acoustics</style></keyword><keyword><style face="normal" font="default" size="100%">New York</style></keyword><keyword><style face="normal" font="default" size="100%">Singapore</style></keyword><keyword><style face="normal" font="default" size="100%">Hong Kong</style></keyword><keyword><style face="normal" font="default" size="100%">Kuala Lumpur Malaysia</style></keyword><keyword><style face="normal" font="default" size="100%">Riyadh Saudi Arabia</style></keyword><keyword><style face="normal" font="default" size="100%">Switzerland</style></keyword><keyword><style face="normal" font="default" size="100%">Utah</style></keyword><keyword><style face="normal" font="default" size="100%">Bangkok Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">Fort Worth Texas</style></keyword><keyword><style face="normal" font="default" size="100%">Beijing China</style></keyword><keyword><style face="normal" font="default" size="100%">Cairo Egypt</style></keyword><keyword><style face="normal" font="default" size="100%">Baton Rouge Louisiana</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">Montreal Quebec Canada</style></keyword><keyword><style face="normal" font="default" size="100%">Ohio</style></keyword><keyword><style face="normal" font="default" size="100%">Calgary Alberta Canada</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 2016&#xD;2018-10-07</style></date></pub-dates></dates><pub-location><style face="normal" font="default" size="100%">Basel</style></pub-location><publisher><style face="normal" font="default" size="100%">S. Karger AG</style></publisher><isbn><style face="normal" font="default" size="100%">10217762</style></isbn><accession-num><style face="normal" font="default" size="100%">1816221878</style></accession-num><abstract><style face="normal" font="default" size="100%">Guzman, M. (Santiago); Calvache, C. (Bogot); Romero, L.; Muoz, D.; Olavarria, C.; Madrid, S.; Leiva, M.; Bortnem, C. (Santiago) 76 The Effect of Loudness Variation on Velopharyngeal Function in Children with 22q11.2 Deletion Syndrome: A Pilot Study Cummings, C.; McCauley, R.; Baylis, A. (Columbus, Ohio) E-Mail karger@karger.com www.karger.com 2016 S. Karger AG, Basel Access to full text and tables of contents, including tentative ones for forthcoming issues: www.karger.com/fpl_issues 83 Effects of Congenital Visual Deprivation on the Auditory Perception of Anticipatory Labial Coarticulation Mnard, L. (Montreal, Que.); Cathiard, M.-A.; Troille, E. (Grenoble); Giroux, M. (Montreal, Que.) 90 Cepstral, Spectral and Time-Based Analysis of Voices of Esophageal Speakers Shim, H.-J.; Jang, H.R.; Shin, H.B.; Ko, D.-H. (Chuncheon) Review 97 Effects of Repetitive Transcranial Magnetic Stimulation in the Rehabilitation of Communication and Deglutition Disorders: Systematic Review of Randomized Controlled Trials Gadenz, C.D.; Moreira, T.d.C.; Capobianco, D.M.; Cassol, M. (Porto Alegre) 75 Erratum 106 IALP News No. 3 Quality of Life in Aphasia Guest Editor: Klippi, A. (Helsinki) 113 Preface Klippi, A. (Helsinki) Editorial 114 Quality of Life in Aphasia: State of the Art Hilari, K.; Cruice, M. (London); Sorin-Peters, R. (Toronto, Ont.); Worrall, L. (Brisbane, Qld.) Original Papers 119 An International Perspective on Quality of Life in Aphasia: A Survey of Clinician Views and Practices from Sixteen Countries Hilari, K. (London); Klippi, A. (Helsinki); Constantinidou, F. (Nicosia); Horton, S. (Norwich); Penn, C. (Johannesburg); Raymer, A. (Norfolk, Va.); Wallace, S. (Brisbane, Qld.); Zemva, N. (Ljubljana); Worrall, L. (Brisbane, Qld.) 131 Practitioners Perspectives on Quality of Life in Aphasia Rehabilitation in Denmark Cruice, M. (London); Isaksen, J. (Odense); Randrup-Jensen, L. (Copenhagen); EggersViberg, M. (Odense/Copenhagen); tenKate, O. (London) 145 Cognitive-Linguistic Performance and Quality of Life in Healthy Aging Constantinidou, F.; Prokopiou, J.; Nikou, M.; Papacostas, S. (Nicosia)156 Living with Aphasia the Best Way I Can: A Feasibility Study Exploring Solution-Focused Brief Therapy for People with Aphasia Northcott, S.; Burns, K.; Simpson, A.; Hilari, K. (London) 168 Author Index/Subject Index No. 4 Review 169 Reading in Autism Spectrum Disorders: A Literature Review Fernandes, F.D.M.; deLaHigueraAmato, C.A. (So Paulo); Cardoso, C. (Salvador); Navas, A.L.G.P.; Molini-Avejonas, D.R. (So Paulo) Original Papers 178 Characteristics of a Dysphonic Population Referred for Voice Assessment and/or Voice Therapy DeBodt, M. (Antwerp/Gent); VandenSteen, L. (Antwerp); Mertens, F. (Turnhout); Raes, J. (Brussels); VanBel, L.; Heylen, L.; Pattyn, J. (Turnhout); Gordts, F. (Brussels); vandeHeyning, P. (Antwerp) 187 Influence of Demographic Variables on Metalinguistic Skills Cadrio, I.; Lousada, M. (Aveiro)193 A Participatory Design Approach to Develop a Web-Based Self-Care Program Supporting Early Rehabilitation among Patients after Total Laryngectomy Cnossen, I.C.; vanUden-Kraan, C.F.; Eerenstein, S.E.J.; Rinkel, R.N.P.M.; Aalders, IJ.J.; vandenBerg, K.; deGoede, C.J.T.; vanStijgeren, A.J.; Cruijff-Bijl, Y. (Amsterdam); deBree, R. (Amsterdam/Utrecht); Leemans, C.R.; Verdonck-deLeeuw, I.M. (Amsterdam) 202 Simultaneous Measurement of Breathing Kinematics and Surface Electromyography of Chest Wall Muscles during Maximum Performance and Speech Tasks in Children: Methodological Considerations Clair-Auger, J.M. (Edmonton, Alta.); Gan, L.S. (Calgary, Alta.); Norton, J.A. (Edmonton, Alta./Saskatoon, Sask.); Boliek, C.A. (Edmonton, Alta.) 212 Protocol for the Evaluation of Speech Intelligibility in Dysarthrias: Evidence of Reliability and Validity dosSantosBarreto, S.; ZazoOrtiz, K. (So Paulo) 219 IALP News No. 5 Original Papers 221 Measuring Stuttering in Preschool-Aged Children across Different Languages: An International Study Bosshardt, H.-G. (Bochum); Packman, A. (Sydney, N.S.W.); Blomgren, M. (Salt Lake City, Utah); Kretschmann, J. (Bochum) 231 Validation and Cultural Adaptation of the Arabic Version of the Eating Assessment Tool (EAT-10) Farahat, M. (Riyadh); Mesallam, T.A. (Riyadh/Shebin Alkoum)238 Normative Nasalance Scores for Brazilian Portuguese Using New Speech Stimuli Marino, V.C.C. (Marlia); Dutka, J.C.R. (Bauru); deBoer, G. (Toronto, Ont.); Cardoso, V.M.; Ramos, R.G. (Marlia); Bressmann, T. (Toronto, Ont.) 245 Familiarization Effects on Consonant Intelligibility in Dysarthric Speech Kim, H. (Urbana, Ill.)253 Nonword Repetition in Spanish-Speaking Toddlers with and without Early Language Delays Guiberson, M. (Laramie, Wyo.); Rodrguez, B.L. (Albuquerque, N.Mex.) 259 Stable Voice Clusters Identified When Using the Maximum versus Minimum Intensity Curve in the Phonetogram Camarrone, F.; Ivanova, A.; Decoster, W.; deJong, F.; vanHulle, M.M. (Leuven) 267 IALP News No. 6 Main Reports 269 Expanding Instrumental Options for Dysphagia Diagnosis and Research: Ultrasound and Manometry Huckabee, M.-L.; Macrae, P.; Lamvik, K. (Christchurch)285 Neuroscientific Implications in Assessment and Intervention for Aphasia Worrall, L.; Brandenburg, C.; Shrubsole, K. (Brisbane, Qld.)293 What Factors Influence Language Impairment?</style></abstract><label><style face="normal" font="default" size="100%">review</style></label><notes><style face="normal" font="default" size="100%">Name - Karger AG&#xD;Copyright - © 2016 S. Karger AG, Basel&#xD;SubjectsTermNotLitGenreText - Riyadh Saudi Arabia; Beijing China; Montreal Quebec Canada; Denmark; Hong Kong; Fort Worth Texas; Utah; Cairo Egypt; Switzerland; New York; Kuala Lumpur Malaysia; Bangkok Thailand; Ohio; Singapore; Baton Rouge Louisiana; Calgary Alberta Canada</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ezproxy.library.arizona.edu/login?url=https://search.proquest.com/docview/1816221878?accountid=8360</style></url><url><style face="normal" font="default" size="100%">https://arizona-primo.hosted.exlibrisgroup.com/openurl/01UA/01UA?&amp;aufirst=&amp;aulast=&amp;atitle=Contents+Vol.+67%2C+2015&amp;title=Contents+Vol.+67%2C+2015&amp;volume=67&amp;date=2016&amp;spage=I&amp;issn=10217762</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">1</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1159/000447661</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Linguistics and Language Behavior Abstracts (LLBA)</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language><modified-date><style face="normal" font="default" size="100%">1</style></modified-date></record><record><database name="rTMS_discussion_static_groups.enl" path="/Volumes/Main/Working/Kielar_MetaAnalysis_2020/rTMS_discussion_static_groups.enl">rTMS_discussion_static_groups.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>74</rec-number><foreign-keys><key app="EN" db-id="sdaareav6zpdpeep0rb5trdqdxpwpxt225tv">74</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abdul, M.</style></author><author><style face="normal" font="default" size="100%">Riviello Jr, J. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.J. Riviello Jr., Section of Neurology and Developmental Neuroscience, Baylor College of Medicine, Texas Children&apos;s Hospital, 6621 Fannin, Houston, TX 77030, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Update on the newer antiepileptic drugs in child neurology: Advances in treatment of pediatric epilepsy</style></title><secondary-title><style face="normal" font="default" size="100%">Current Treatment Options in Neurology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Treatment Options in Neurology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">395-403</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">4 aminobutyric acid receptor</style></keyword><keyword><style face="normal" font="default" size="100%">acetazolamide</style></keyword><keyword><style face="normal" font="default" size="100%">anticonvulsive agent</style></keyword><keyword><style face="normal" font="default" size="100%">benzodiazepine derivative</style></keyword><keyword><style face="normal" font="default" size="100%">carbamazepine</style></keyword><keyword><style face="normal" font="default" size="100%">clobazam</style></keyword><keyword><style face="normal" font="default" size="100%">clonazepam</style></keyword><keyword><style face="normal" font="default" size="100%">diazepam</style></keyword><keyword><style face="normal" font="default" size="100%">ethosuximide</style></keyword><keyword><style face="normal" font="default" size="100%">ethotoin</style></keyword><keyword><style face="normal" font="default" size="100%">etiracetam</style></keyword><keyword><style face="normal" font="default" size="100%">felbamate</style></keyword><keyword><style face="normal" font="default" size="100%">gabapentin</style></keyword><keyword><style face="normal" font="default" size="100%">glutamate receptor</style></keyword><keyword><style face="normal" font="default" size="100%">lamotrigine</style></keyword><keyword><style face="normal" font="default" size="100%">lorazepam</style></keyword><keyword><style face="normal" font="default" size="100%">mesuximide</style></keyword><keyword><style face="normal" font="default" size="100%">n methyl dextro aspartic acid</style></keyword><keyword><style face="normal" font="default" size="100%">new drug</style></keyword><keyword><style face="normal" font="default" size="100%">oxcarbazepine</style></keyword><keyword><style face="normal" font="default" size="100%">phenobarbital</style></keyword><keyword><style face="normal" font="default" size="100%">phenytoin</style></keyword><keyword><style face="normal" font="default" size="100%">pregabalin</style></keyword><keyword><style face="normal" font="default" size="100%">sultiame</style></keyword><keyword><style face="normal" font="default" size="100%">tiagabine</style></keyword><keyword><style face="normal" font="default" size="100%">topiramate</style></keyword><keyword><style face="normal" font="default" size="100%">unindexed drug</style></keyword><keyword><style face="normal" font="default" size="100%">valproic acid</style></keyword><keyword><style face="normal" font="default" size="100%">vigabatrin</style></keyword><keyword><style face="normal" font="default" size="100%">zonisamide</style></keyword><keyword><style face="normal" font="default" size="100%">absence</style></keyword><keyword><style face="normal" font="default" size="100%">acidosis</style></keyword><keyword><style face="normal" font="default" size="100%">aggression</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia</style></keyword><keyword><style face="normal" font="default" size="100%">aplastic anemia</style></keyword><keyword><style face="normal" font="default" size="100%">asthenia</style></keyword><keyword><style face="normal" font="default" size="100%">ataxia</style></keyword><keyword><style face="normal" font="default" size="100%">behavior</style></keyword><keyword><style face="normal" font="default" size="100%">behavior disorder</style></keyword><keyword><style face="normal" font="default" size="100%">benign childhood epilepsy</style></keyword><keyword><style face="normal" font="default" size="100%">childhood disease</style></keyword><keyword><style face="normal" font="default" size="100%">cognition</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">complex partial seizure</style></keyword><keyword><style face="normal" font="default" size="100%">concentration loss</style></keyword><keyword><style face="normal" font="default" size="100%">confusion</style></keyword><keyword><style face="normal" font="default" size="100%">consensus</style></keyword><keyword><style face="normal" font="default" size="100%">cost effectiveness analysis</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">disease course</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">drowsiness</style></keyword><keyword><style face="normal" font="default" size="100%">drug cost</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose escalation</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose increase</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose titration</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug eruption</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">drug induced headache</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug overdose</style></keyword><keyword><style face="normal" font="default" size="100%">drug potentiation</style></keyword><keyword><style face="normal" font="default" size="100%">drug receptor binding</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">emotional disorder</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme inhibition</style></keyword><keyword><style face="normal" font="default" size="100%">epilepsy</style></keyword><keyword><style face="normal" font="default" size="100%">epileptic state</style></keyword><keyword><style face="normal" font="default" size="100%">face edema</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">febrile convulsion</style></keyword><keyword><style face="normal" font="default" size="100%">focal epilepsy</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">tonic clonic seizure</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperactivity</style></keyword><keyword><style face="normal" font="default" size="100%">hyperkinesia</style></keyword><keyword><style face="normal" font="default" size="100%">infantile spasm</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">injection site burning</style></keyword><keyword><style face="normal" font="default" size="100%">injection site reaction</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">irritability</style></keyword><keyword><style face="normal" font="default" size="100%">Lennox Gastaut syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">liver failure</style></keyword><keyword><style face="normal" font="default" size="100%">liver toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">medical expert</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">mood disorder</style></keyword><keyword><style face="normal" font="default" size="100%">myoclonus epilepsy</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">nephrolithiasis</style></keyword><keyword><style face="normal" font="default" size="100%">nervousness</style></keyword><keyword><style face="normal" font="default" size="100%">neurology</style></keyword><keyword><style face="normal" font="default" size="100%">neurotoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">paresthesia</style></keyword><keyword><style face="normal" font="default" size="100%">protein synthesis inhibition</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">restlessness</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">seizure</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">somnolence</style></keyword><keyword><style face="normal" font="default" size="100%">speech disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">stupor</style></keyword><keyword><style face="normal" font="default" size="100%">taste disorder</style></keyword><keyword><style face="normal" font="default" size="100%">toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default" size="100%">tremor</style></keyword><keyword><style face="normal" font="default" size="100%">unspecified side effect</style></keyword><keyword><style face="normal" font="default" size="100%">urine retention</style></keyword><keyword><style face="normal" font="default" size="100%">vagus nerve stimulation</style></keyword><keyword><style face="normal" font="default" size="100%">visual field defect</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">body weight gain</style></keyword><keyword><style face="normal" font="default" size="100%">body weight loss</style></keyword><keyword><style face="normal" font="default" size="100%">diastat</style></keyword><keyword><style face="normal" font="default" size="100%">gabitril</style></keyword><keyword><style face="normal" font="default" size="100%">keppra</style></keyword><keyword><style face="normal" font="default" size="100%">lyrica</style></keyword><keyword><style face="normal" font="default" size="100%">neurontin</style></keyword><keyword><style face="normal" font="default" size="100%">topamax</style></keyword><keyword><style face="normal" font="default" size="100%">trileptal</style></keyword><keyword><style face="normal" font="default" size="100%">zonegran</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><isbn><style face="normal" font="default" size="100%">1092-8480</style></isbn><abstract><style face="normal" font="default" size="100%">The goal of epilepsy treatment is the prevention of recurrent seizures, and anti-epileptic drugs (AEDs) are the mainstay. Uncontrolled seizures may cause medical, developmental, and psychologic disturbances. Treatment advances include 1) identification of the basic mechanisms of epilepsy and action of AEDs, 2) the introduction of many new AEDs, and 3) the use of neurostimulation, starting with vagus nerve stimulation. We must balance the efficacy of an AED versus its side effects, which if persistent, lead to patient discontinuation of the AED. Although all AEDs have a proven efficacy, they are differentiated by their efficacy for a given seizure type or epilepsy syndrome versus the side effects or tolerability. The many new AEDs give us a larger armamentarium for epilepsy treatment. We refer to studies and expert opinion consensus. Copyright © 2007 by Current Medicine Group LLC.</style></abstract><label><style face="normal" font="default" size="100%">not aphasia</style></label><notes><style face="normal" font="default" size="100%">L350081464&#xD;2007-11-29</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L350081464</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s11940-007-0041-2</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">diastat(Valeant,United States)&#xD;gabitril(Cephalon,United States)&#xD;keppra(UCB,Belgium)&#xD;lyrica(Pfizer)&#xD;neurontin(Pfizer,United States)&#xD;topamax(Ortho McNeil,United States)&#xD;trileptal(Novartis,Switzerland)&#xD;zonegran(Eisai,United States)</style></custom1><custom2><style face="normal" font="default" size="100%">Cephalon(United States)&#xD;Eisai(United States)&#xD;Novartis(Switzerland)&#xD;Ortho McNeil(United States)&#xD;Pfizer(United States)&#xD;UCB(Belgium)&#xD;Valeant(United States)</style></custom2><custom7><style face="normal" font="default" size="100%">1</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11940-007-0041-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language><modified-date><style face="normal" font="default" size="100%">1</style></modified-date></record><record><database name="rTMS_discussion_static_groups.enl" path="/Volumes/Main/Working/Kielar_MetaAnalysis_2020/rTMS_discussion_static_groups.enl">rTMS_discussion_static_groups.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>75</rec-number><foreign-keys><key app="EN" db-id="sdaareav6zpdpeep0rb5trdqdxpwpxt225tv">75</key></foreign-keys><ref-type name="Generic">13</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shirley Ryan AbilityLab</style></author><author><style face="normal" font="default" size="100%">Honda</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Development of Walk Assist Device to Improve Community Ambulation</style></title></titles><keywords><keyword><style face="normal" font="default" size="100%">Stroke</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">October</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">https://ClinicalTrials.gov/show/NCT01994395</style></publisher><accession-num><style face="normal" font="default" size="100%">NCT01994395</style></accession-num><label><style face="normal" font="default" size="100%">not TMS</style></label><notes><style face="normal" font="default" size="100%">Has Results&#xD;Device: The Stride Management Assist (SMA) System|Other: Impairment based therapy&#xD;Change in 10 Meter Walk Test From Baseline in Gait Speed|Activities-Specific Balance Confidence Scale (ABC)|Numeric Pain Rating Scale (NPRS)|Stroke Specific Quality of Life Scale (SS-QOL)|The Modified Falls Efficacy Scale (mFES)|Patient Health Questionnaire-9 (PHQ-9)|Participants Receiving Transcranial Magnetic Stimulation (TMS)|Change in 6 Minute Walk Test From Baseline in Distance (6MWT)|Berg Balance Scale (BBS)&#xD;All&#xD;Not Applicable&#xD;53&#xD;Other&#xD;Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment&#xD;NUSTU00085161&#xD;February 2020</style></notes><urls></urls><custom7><style face="normal" font="default" size="100%">1</style></custom7><remote-database-name><style face="normal" font="default" size="100%">ClinicalTrials.gov</style></remote-database-name><modified-date><style face="normal" font="default" size="100%">1</style></modified-date></record><record><database name="rTMS_discussion_static_groups.enl" path="/Volumes/Main/Working/Kielar_MetaAnalysis_2020/rTMS_discussion_static_groups.enl">rTMS_discussion_static_groups.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>76</rec-number><foreign-keys><key app="EN" db-id="sdaareav6zpdpeep0rb5trdqdxpwpxt225tv">76</key></foreign-keys><ref-type name="Generic">13</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shirley Ryan AbilityLab</style></author><author><style face="normal" font="default" size="100%">Nexstim Ltd</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Contrastim Stroke Trial</style></title><short-title><style face="normal" font="default" size="100%">ContraStim</style></short-title></titles><keywords><keyword><style face="normal" font="default" size="100%">Stroke</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style face="normal" font="default" size="100%">January</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">https://ClinicalTrials.gov/show/NCT01049802</style></publisher><accession-num><style face="normal" font="default" size="100%">NCT01049802</style></accession-num><label><style face="normal" font="default" size="100%">not an article</style></label><notes><style face="normal" font="default" size="100%">Has Results&#xD;Device: Repetititve transcranial magnetic stimulation&#xD;Upper Extremity Fugl-Meyer Score|Action Research Arm Test|Stroke Impact Scale|Chedoke Arm Assessment|NIH Stroke Scale&#xD;All&#xD;Phase 1|Phase 2&#xD;30&#xD;Other|Industry&#xD;Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment&#xD;NR-001&#xD;September 2016</style></notes><urls></urls><custom7><style face="normal" font="default" size="100%">1</style></custom7><remote-database-name><style face="normal" font="default" size="100%">ClinicalTrials.gov</style></remote-database-name><modified-date><style face="normal" font="default" size="100%">1</style></modified-date></record><record><database name="rTMS_discussion_static_groups.enl" path="/Volumes/Main/Working/Kielar_MetaAnalysis_2020/rTMS_discussion_static_groups.enl">rTMS_discussion_static_groups.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>77</rec-number><foreign-keys><key app="EN" db-id="sdaareav6zpdpeep0rb5trdqdxpwpxt225tv">77</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ackermann, H.</style></author><author><style face="normal" font="default" size="100%">Gräber, S.</style></author><author><style face="normal" font="default" size="100%">Hertrich, I.</style></author><author><style face="normal" font="default" size="100%">Daum, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">H. Ackermann, Department of Neurology, University of Tubingen, Hoppe-Seyler-Strasse 3, D-72076 Tubingen, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Phonemic vowel length contrasts in cerebellar disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Brain and Language</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">95-109</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">acoustics</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">apraxia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">cerebellar ataxia</style></keyword><keyword><style face="normal" font="default" size="100%">cerebellum atrophy</style></keyword><keyword><style face="normal" font="default" size="100%">cerebellum disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">dysarthria</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nuclear magnetic resonance spectroscopy</style></keyword><keyword><style face="normal" font="default" size="100%">phoneme</style></keyword><keyword><style face="normal" font="default" size="100%">transcranial magnetic stimulation</style></keyword><keyword><style face="normal" font="default" size="100%">vowel</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1999</style></year></dates><isbn><style face="normal" font="default" size="100%">0093-934X</style></isbn><abstract><style face="normal" font="default" size="100%">Apraxia of speech and Broca&apos;s aphasia both affect voice onset time (VOT) whereas phonemic vowel length distinctions seem to be preserved. Assuming a close cooperation of anterior perisylvian language zones and the cerebellum with respect to speech timing, a similar profile of segment durations must be expected in ataxic dysarthria. In order to test this hypothesis, patients with cerebellar atrophy or cerebellar ischemia were asked to produce sentence utterances including either one of the German lexial items &apos;Rate&apos; (/ra:t(h)e/, &apos;installment&apos;), &apos;Ratte&apos; (/rat(h)e/, &apos;rat&apos;), &apos;Gram&apos; (/gra:m/, &apos;grief&apos;), &apos;Gramm&apos; (/gram/, &apos;gramm&apos;), Taten (/t(h)n/, &apos;actions&apos;), or &apos;Daten&apos; (/datn/, &apos;data&apos;). At the acoustic signal, the duration of the target vowels /a/ and /a:/ as well as the VOT of the word-initial alveolar stops /d/ and /t/ were determined. In addition, a master tape comprising the target words from patients and controls in randomized order was played to three listeners for perceptual evaluation. In accordance with a previous study, first, the cerebellar subjects presented with a reduced categorical separation of the VOT of voiced and unvoiced stop consonants. Second, vowel length distinctions were only compromised in case of the minimal pair &apos;Gram&apos;/&apos;Gramm.&apos; In contrast to &apos;Rate&apos;/&apos;Ratte&apos;, production of the former lexical items requires coordination of several orofacial structures. Disruption of vowel length contrasts would, thus, depend upon the complexity of the underlying articulatory pattern.</style></abstract><label><style face="normal" font="default" size="100%"> not aphasia</style></label><notes><style face="normal" font="default" size="100%">L29370187&#xD;1999-08-16</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L29370187</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1006/brln.1998.2044</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">10092344</style></custom5><custom7><style face="normal" font="default" size="100%">1</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1006/brln.1998.2044</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language><modified-date><style face="normal" font="default" size="100%">1</style></modified-date></record></records></xml>